CRP and prostate carcinoma: Systemic inflammatory biomarkers, including C-reactive protein, composite inflammatory indices such as the systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio, provide accessible measures of systemic inflammatory burden with significant prognostic utility in prostate cancer prediction and outcome assessment.